Testing new antibiotics to treat highly resistant bacterial infections is especially difficult, since only a small number of patients contract such infections or meet the requirements to participate in clinical trials. Following are examples of hard-to-treat pathogens that present the greatest unmet needs today, and the types of drugs that are most likely to address them.More info
WASHINGTON—The U.S. House of Representatives Wednesday passed the Food and Drug Administration Safety and Innovation Act (S. 3187), a bill to support the FDA’s drug and device reviews.
"We commend the House for passing the bipartisan Food and Drug Administration Safety and Innovation Act," said Allan Coukell, director of medical programs at the Pew Health Group. "This legislation will help deliver safe, effective and innovative medical products to patients. We also commend the Energy and Commerce Committee for its leadership throughout this process. We look forward to the bill’s passage through the U.S. Senate."
- Date added:
- Jun 21, 2012
The President’s Council of Advisors on Science and Technology held a public meeting on April 4 to discuss the issue of antimicrobial resistance. Drug safety and innovation director Elizabeth Jungman testified on the need to spur the development of new antibacterial drugs.More info
Allan Coukell, senior director of drugs and medical devices, testified before the U.S.-China Economic and Security Review Commission on the global pharmaceutical supply chain security and the importance of the newly passed Drug Quality and Security Act.More info